A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
Nick Thatcher
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Fred R. Hirsch
Consultant or Advisory Role - Lilly/ImClone (U)
Research Funding - Lilly/ImClone
Aleksandra Szczesna
No relevant relationships to disclose
Tudor-Eliade Ciuleanu
Honoraria - Lilly
Wojciech Szafranski
No relevant relationships to disclose
Mircea Dediu
Honoraria - Amgen
Rodryg Ramlau
Consultant or Advisory Role - Lilly
Honoraria - Lilly
Rinat Galiulin
No relevant relationships to disclose
Beatrix Bálint
Employment or Leadership Position - Hospital Csongrád Megye Mellkasi Betegségek Szakkórháza
Research Funding - PPD Hungary Ltd; CP11-0805, CP110806 studies
Gyorgy Losonczy
No relevant relationships to disclose
Andrzej Kazarnowicz
No relevant relationships to disclose
Keunchil Park
No relevant relationships to disclose
Christian Schumann
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Luis Paz-Ares
Honoraria - Lilly
Henrik Depenbrock
Employment or Leadership Position - Lilly Deutschland GmbH
Stock Ownership - Lilly
Shivani Nanda
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Anamarija Kruljac-Letunic
Employment or Leadership Position - Lilly Deutschland GmbH
Mark A. Socinski
Research Funding - Lilly